These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 17007995

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 3. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J.
    Eur Urol; 1997 Jan; 32 Suppl 3():78-80. PubMed ID: 9267790
    [Abstract] [Full Text] [Related]

  • 6. Endocrine therapy for prostate cancer.
    Damber JE.
    Acta Oncol; 2005 Jan; 44(6):605-9. PubMed ID: 16165920
    [Abstract] [Full Text] [Related]

  • 7. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens.
    Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, Ross SD.
    Urology; 1997 Jan; 49(1):71-8. PubMed ID: 9000189
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    BJU Int; 2015 Jul; 116(1):30-6. PubMed ID: 25523493
    [Abstract] [Full Text] [Related]

  • 12. An oncology perspective on the benefits and cost of combined androgen blockade in advanced prostate cancer.
    Aprikian AG, Fleshner N, Langleben A, Hames J.
    Can J Urol; 2003 Oct; 10(5):1986-94. PubMed ID: 14633326
    [Abstract] [Full Text] [Related]

  • 13. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
    Gillatt D.
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S17-26. PubMed ID: 16845534
    [Abstract] [Full Text] [Related]

  • 14. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
    Abrahamsson PA, Anderson J, Boccon-Gibod L, Schulman C, Studer UE, Wirth M.
    Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study.
    Ueno S, Namiki M, Fukagai T, Ehara H, Usami M, Akaza H.
    Int J Urol; 2006 Dec; 13(12):1494-500. PubMed ID: 17118024
    [Abstract] [Full Text] [Related]

  • 16. Combination hormonal therapy: a reassessment within advanced prostate cancer.
    Moul JW, Chodak G.
    Prostate Cancer Prostatic Dis; 2004 Sep; 7 Suppl 1():S2-7. PubMed ID: 15365575
    [Abstract] [Full Text] [Related]

  • 17. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F, Buzzatti G, Rubagotti A, Boccardo F.
    Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
    [Abstract] [Full Text] [Related]

  • 18. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [Abstract] [Full Text] [Related]

  • 19. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R.
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [Abstract] [Full Text] [Related]

  • 20. Overview of current status of total androgen deprivation in metastasized prostate cancer.
    Debruyne FM, Witjes WP.
    Eur Urol; 1993 Oct; 24 Suppl 2():67-71. PubMed ID: 8262129
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.